Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that recently, the company's subsidiaries Shanghai Shengdi Pharmaceutical Co., Ltd. and Suzhou Shengdiya Biomedical Co., Ltd. received the clinical trial approval notification issued by the National Medical Products Administration (referred to as "National Drug Administration") regarding the injection of SHR-4602, injection of SHR-A1811, Adalimumab injection, and SHR-8068 injection, and clinical trials will be conducted in the near future.
恒瑞医药：子公司部分药品获药物临床试验批准通知书
Jiangsu Hengrui Pharmaceuticals: A subsidiary has received the clinical trial approval notification for certain pharmaceuticals.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated